-+ 0.00%
-+ 0.00%
-+ 0.00%

TD Cowen Maintains Hold on Myriad Genetics, Lowers Price Target to $6

Benzinga·05/06/2026 19:39:44
Listen to the news
TD Cowen analyst Kyle Boucher maintains Myriad Genetics (NASDAQ:MYGN) with a Hold and lowers the price target from $7 to $6.